Literature DB >> 11464909

Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1.

E Hiyama1, K Hiyama, K Ohtsu, H Yamaoka, I Fukuba, Y Matsuura, T Yokoyama.   

Abstract

BACKGROUND: Neuroblastoma shows remarkable heterogeneity, resulting in favorable and unfavorable outcomes. It is well known that almost all cases with MYCN amplification have a poor prognosis. We have previously reported that unfavorable tumors show high telomerase activity, whereas favorable tumors show low or nil activity. We also found that the unfavorable neuroblastoma often have a loss of heterozygosity (LOH) at the MYCL locus. PROCEDURE: To clarify the biological and clinical profiles of tumors with genetic abnormalities of the short arm of chromosome 1, we performed deletion mapping on 1p on 92 neuroblastoma tissues and corresponding noncancerous samples obtained from 92 cases for 24 micro- or minisatellite loci.
RESULTS: LOH was detected in at least one locus of 1p in 43 (47%) cases. All samples were classified into four groups according to the deleted pattern: interstitial deletion (group I, n = 20), short terminal deletion (group ST, n = 6), large terminal deletion (group LT, n = 17), and without detectable deletion (group N, n = 49). All group I cases, whose SRO (shortest region of overlap) was at 1p36.1-2, survived disease free, and none of them showed MYCN amplification or high telomerase activity except for one case. On the other hand, in group LT cases, who showed a large terminal deletion from D1S162 (1p32-pter), including the SRO of group 1, only 5 out of 17 have survived disease free, and 13 showed MYCN amplification or high telomerase activity. The six group ST cases showed small terminal deletion from 1p36.3 with modest prognosis, similar to the group N.
CONCLUSIONS: Thus, we propose three loci, 1p36.1-2, 1p32-34, and 1p36.3, as the candidate loci of neuroblastoma suppressor genes on chromosome 1p responsible for groups I, LT, and ST, respectively. Among them, the 1p32-34 locus may be associated with aggressiveness of tumor progression, possibly due to MYCN amplification and/or telomerase reactivation, while the remaining two loci may not.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464909     DOI: 10.1002/1096-911X(20010101)36:1<67::AID-MPO1017>3.0.CO;2-S

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

1.  A unique role of the DNA fragmentation factor in maintaining genomic stability.

Authors:  Bin Yan; Huili Wang; Yuanlin Peng; Ye Hu; He Wang; Xiuwu Zhang; Qi Chen; Joel S Bedford; Mark W Dewhirst; Chuan-Yuan Li
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

2.  Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.

Authors:  Masato Kojima; Eiso Hiyama; Ikuko Fukuba; Emi Yamaoka; Yuka Ueda; Yoshiyuki Onitake; Shou Kurihara; Taijiro Sueda
Journal:  Pediatr Surg Int       Date:  2013-11       Impact factor: 1.827

3.  Heterogeneous subgroups in human neuroblastoma for clinically relevant risk stratification.

Authors:  Eiso Hiyama; Hiroaki Yamaoka; Satoshi Kondo; Akihiro Yoneda; Tatsuro Tajiri; Masahiro Fukuzawa; Masahiko Sugiyama; Yutaka Hayashi; Fumiaki Sasaki; Megu Ohtaki
Journal:  Pediatr Surg Int       Date:  2007-08-16       Impact factor: 1.827

Review 4.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

5.  Ultrastructural features of neuroblastic tumours in relation to morphological, and molecular findings; a retrospective review study.

Authors:  Elizabeth Latimer; Glenn Anderson; Neil James Sebire
Journal:  BMC Clin Pathol       Date:  2014-03-31

6.  In Vitro Transfection of Up-Regulated Genes Identified in Favorable-Outcome Neuroblastoma into Cell Lines.

Authors:  Yoko Hiyama; Emi Yamaoka; Takahiro Fukazawa; Masato Kojima; Yusuke Sotomaru; Eiso Hiyama
Journal:  Cells       Date:  2022-10-10       Impact factor: 7.666

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.